NCT02268929

Brief Summary

This study is a German, prospective, multicenter, controlled, cluster-randomized, interventional comparative study evaluating the efficacy and benefits of integrated PDM care by measuring HbA1c levels in patients with Type 2 Diabetes. Patients will be randomized into two groups to use Accu-Chek Smartpix software and Accu-Chek Smartpix device.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
414

participants targeted

Target at P75+ for not_applicable diabetes-mellitus-type-2

Timeline
Completed

Started Oct 2014

Typical duration for not_applicable diabetes-mellitus-type-2

Geographic Reach
1 country

50 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 14, 2014

Completed
2 days until next milestone

First Submitted

Initial submission to the registry

October 16, 2014

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 20, 2014

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 11, 2017

Completed
29 days until next milestone

Study Completion

Last participant's last visit for all outcomes

February 9, 2017

Completed
Last Updated

November 24, 2017

Status Verified

November 1, 2017

Enrollment Period

2.2 years

First QC Date

October 16, 2014

Last Update Submit

November 22, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • The mean HbA1c change by Generalized Estimating Equations (GEE) methods

    from Baseline to 12 months

Secondary Outcomes (1)

  • Effects of integrated Personalized Diabetes Management (PDM) by means of Generalized Estimating Equations [GEE] methods

    12 months

Study Arms (2)

Control Group

OTHER

Patients treated by usual customary medical practice (Usual Care)

Device: Accu-Chek Smart Pix readout Device

Intervention Group

OTHER

Patients treated with "Integrated Personalized Diabetes Management"

Device: Accu-Chek Smart Pix Software

Interventions

Software with adherence evaluation software used according to Integrated Personalized Diabetes Management (PDM)

Intervention Group

Smartpix device for data upload out from blood glucose meter devices

Control Group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Existence of a signed Informed Consent form (before any study procedure)
  • Diagnosed Type 2 diabetes mellitus
  • Age =18 years
  • Insulin therapy for =6 months: BOT, SIT, CT or ICT
  • Longer-term diabetes care by the trial site (at least for the duration of the 12-month study participation)
  • General practitioner is the primary practitioner in the diabetes care of the patient
  • Insured by the statutory health insurance (GKV) as a statutory or voluntarily insured member or as a family co-insured member
  • Willing and able to participate in the study and to follow the study procedures, among other things sufficient command of the German language, spoken and written

You may not qualify if:

  • Diabetes treatment by insulin pump therapy (CSII)
  • Experience with the use of special software for systematic processing of SMBG data, e.g. the Accu-Chek® Smart Pix System/Software, the Accu-Chek® 360° Software and/or the Diabetes Software DIABASS
  • Presence of terminal renal failure / dialysis and/or a loss of sight or a tumor illness
  • Chronic use of steroids in adrenal suppressant doses, of other immuno-modulatory drugs or chemotherapy
  • Known alcohol, drug and medication abuse
  • Known metabolic disorders and/or disorders or therapies that could lead to or have led to wrong measured results (e.g. with the blood glucose measurement)
  • Existing pregnancy, breast-feeding or plan to become pregnant during study participation
  • Physical illness and/or psychological disorder with the result that the patient cannot implement the medical treatment recommendations independently
  • Dependency relationship to the sponsor or to the investigator, e.g. as a professional colleague or family member

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (50)

Unknown Facility

Albstadt, 72461, Germany

Location

Unknown Facility

Auerbach/Vogtland, 08209, Germany

Location

Unknown Facility

Bad Kreuznach, 55545, Germany

Location

Unknown Facility

Beucha, 04824, Germany

Location

Unknown Facility

Beutel/Templin, 17268, Germany

Location

Unknown Facility

Blankenhain, 99444, Germany

Location

Unknown Facility

Bochum, 44805, Germany

Location

Unknown Facility

Bockenem, 31167, Germany

Location

Unknown Facility

Borna, 04552, Germany

Location

Unknown Facility

Bremerhaven, 27572, Germany

Location

Unknown Facility

Cloppenburg, 49661, Germany

Location

Unknown Facility

Dransfeld, 37127, Germany

Location

Unknown Facility

Dresden, 01309, Germany

Location

Unknown Facility

Düren, 52349, Germany

Location

Unknown Facility

Elsterwerda, 04910, Germany

Location

Unknown Facility

Essen, 45329, Germany

Location

Unknown Facility

Essen, 45355, Germany

Location

Unknown Facility

Essen, 45359, Germany

Location

Unknown Facility

Föhren, 54343, Germany

Location

Unknown Facility

Geringswalde, 09326, Germany

Location

Unknown Facility

Giessen, 35390, Germany

Location

Unknown Facility

Hanover, 30163, Germany

Location

Unknown Facility

Hemsbach, 69502, Germany

Location

Unknown Facility

Herborn, 35745, Germany

Location

Unknown Facility

Kerpen, 50169, Germany

Location

Unknown Facility

Köthen, 06366, Germany

Location

Unknown Facility

Krefeld, 47803, Germany

Location

Unknown Facility

Kreuzau, 52372, Germany

Location

Unknown Facility

Leipzig, 04315, Germany

Location

Unknown Facility

Löhne, 32584, Germany

Location

Unknown Facility

Lübeck, 23562, Germany

Location

Unknown Facility

Mainz, 55116, Germany

Location

Unknown Facility

Mainz, 55130, Germany

Location

Unknown Facility

Meissen, 01662, Germany

Location

Unknown Facility

Meudt, 56414, Germany

Location

Unknown Facility

Papenburg, 26871, Germany

Location

Unknown Facility

Reinfeld, 23858, Germany

Location

Unknown Facility

Riesa, 01589, Germany

Location

Unknown Facility

Rochlitz, 09328, Germany

Location

Unknown Facility

Rodgau, 63110, Germany

Location

Unknown Facility

Schleiden, 53937, Germany

Location

Unknown Facility

Schwedt, 16303, Germany

Location

Unknown Facility

Schweich, 54338, Germany

Location

Unknown Facility

Schweich, 54343, Germany

Location

Unknown Facility

Siegen, 57072, Germany

Location

Unknown Facility

Sigmaringen, 72488, Germany

Location

Unknown Facility

Staufenberg, 35460, Germany

Location

Unknown Facility

Trier, 54290, Germany

Location

Unknown Facility

Weida, 07570, Germany

Location

Unknown Facility

Wetzlar, 35584, Germany

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Officials

  • Iris Vesper

    Roche Diabetes Care

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 16, 2014

First Posted

October 20, 2014

Study Start

October 14, 2014

Primary Completion

January 11, 2017

Study Completion

February 9, 2017

Last Updated

November 24, 2017

Record last verified: 2017-11

Locations